corporate events

(NASDAQ:RGP) DALLAS--(BUSINESS WIRE)--Resources Connection, Inc. (Nasdaq: RGP) (the “Company”), a global consulting firm, today announced that Chief Executive Officer Kate Duchene, Chief Operating Officer Bhadresh Patel, and Chief Financial Officer Jennifer Ryu, will participate in a virtual fireside chat at William Blair’s inaugural Human Capital Services Conference on Wednesday, September 24, 2025 at 11:00 AM Central Time. Management will also host virtual investor meetings throughout the day. For additio

BOCA RATON, FL, Aug. 27, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first U.S. public company built to accumulate Solana’s native token, SOL, today announced it will ring the Nasdaq Closing Bell this Friday, August 29, 2025, at 4:00 p.m. Eastern Time at Nasdaq MarketSite in New York City.

MANAUS, Brazil, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Brazil Potash Corp. ("Brazil Potash" or the "Company") (NYSE-American: GRO) a mineral exploration and development company with a critical mineral potash agriculture project, the Autazes Potash Project, today announced that CEO Matt Simpson, Raphael Bloise, Interim President of Potássio do Brasil and Advisory Board Director, Con Steers, have been formally invited by Mura Indigenous Council - CIM to participate in the annual Mura Indigenous Cultural Festival (FECIM) on August 29 and 30th, 2025.

SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the management team of Journey Medical will ring the closing bell at the Nasdaq MarketSite in Times Square on Monday, August 11, 2025 at 4:00 p.m. ET. Journey Medical is celebrating its 4-year anniversary as a publicly traded company on the Nasdaq Stock Market and the commercial launch of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for the treatment of rosacea.